Combining stereotactic radiosurgery with an epidermal growth factor receptor-tyrosine kinase inhibitor may benefit patients with brain metastases from NSCLC but further study is needed to change standard of care.
New Risk Calculator Bests Other Clinical Measures in Predicting Overall Survival of Patients with Non-Small Cell Lung Cancer
New risk calculator aids clinicians in supporting patients with non-small cell lung cancer
Move to Next-Generation Sequencing of Non-Squamous Non-Small Cell Lung Cancer a Life Saver with Minimal Additional Cost
New model demonstrates lifesaving capabilities of next-generation sequencing for patients with non-squamous non-small cell lung cancer
Second KRAS Inhibitor Represents Another Standard in Patients with Non-Small-Cell Lung Cancer and KRASG12C Mutation
A new treatment option for patients with advanced non-small-cell lung cancer (NSCLC) harboring a KRASG12C mutation is on the horizon.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Achieving Cost-Effectiveness with Adjuvant Osimertinib for NSCLC
Preliminary results from the phase 3 ADAURA trial indicate that osimertinib is superior to placebo in adjuvant treatment of EGFR-mutated non-small cell lung cancer.
Single-Fraction Stereotactic Body Radiation Therapy Effective for Early Stage Lung Cancer
Single-fraction SBRT is safe and effective in treating early stage, medically inoperable NSCLC, according to a ten-year retrospective study of 229 patients, the largest single-institution report to date.
A New Option for Patients with RET Fusion-Positive NSCLC Demonstrates Safety and Efficacy
The selective RET inhibitor selpercatinib is safe and effective in both treated and treatment-naïve patients with RET fusion-positive NSCLC.
NSCLC Patients with Brain Metastases: Look to Molecular Data for Prognostication
Outcomes correlate with the number of brain metastases primarily in patients without two actionable molecular targets: epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
NCI Grant to Cleveland Clinic Scientist Will Support Evolution-Based Cancer Research
A $4 million National Cancer Institute grant will help Cleveland Clinic mathematical oncologist Jacob Scott, MD, DPhil, study how ecological and evolutionary mechanisms contribute to lung cancer development, progression and drug resistance.
Immunotherapy for Non-Small Cell Lung Cancer Brain Metastases: Ready for Prime Time
Two analyses of a large Cleveland Clinic cohort confirm the importance of immunotherapy in treating NSCLC brain metastases and reveal critical indicators of efficacy.